MedTrace Logo

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

NCT02531438 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 774

Last updated 2019-01-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.

Conditions

  • Bacterial Pneumonia
  • Community-Acquired Infections

Interventions

DRUG

Omadacycline

Injection for IV; Oral tablets

DRUG

Moxifloxacin

IV solution; Oral tablets

Sponsors & Collaborators

  • Paratek Pharmaceuticals Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-02-05
Completion
2017-03-10

Countries

  • United States
  • Belgium
  • Brazil
  • Bulgaria
  • Croatia
  • Czechia
  • Georgia
  • Germany
  • Greece
  • Hungary
  • Israel
  • Latvia
  • Mexico
  • Peru
  • Philippines
  • Poland
  • Romania
  • Russia
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02531438 on ClinicalTrials.gov